Oncothyreon's L-BLP25 Did Not Meet Primary Endpoint in Lung Cancer Trial
December 19, 2012 at 06:42 AM EST
Oncothyreon (NASDAQ: ONTY ) today announced that the pivotal Phase 3 clinical trial of L-BLP25 (formerly referred to as Stimuvax®) known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell
